Isis Pharmaceuticals, Inc. (ISIS) Posts Q3 Loss of $0.27, Sales Miss Expectations
Tweet
Share
E-mailGet Alerts ISIS Hot Sheet
Join SI Premium – FREE
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) reported Q3 EPS of ($0.27), $0.07 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $20.7 million versus the consensus estimate of $25.33 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McCormick & Co. (MKC) Tops Q3 EPS by 10c, Beats on Revenue; Offers EPS Guidance
- Precision Optics Corporation, Inc. (POCI) Reports Q4 Loss of $0.01
- ConAgra Brands (CAG) Tops Q1 EPS by 13c, Beats on Revenue; Offers FY27 EPS Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
